Research study Program year 2024 Source: CMS Open Payments

Phase III Inhibitor Study

Research payments

$72,572

17 payments

Through program year 2024, $72,572 in research payments was reported against Phase III Inhibitor Study, across 17 payments.

Paid by (largest first): Genentech, Inc.; F. Hoffmann-La Roche AG
ClinicalTrials.gov: No trial number was reported for this study

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$17,648	7
2023	Research	$4,417	3
2020	Research	$14,602	2
2019	Research	$35,906	5

Breakdown

Who paid Research payments · program years 2019–2024

Genentech, Inc. $50,507 7 payments
F. Hoffmann-La Roche AG $22,065 10 payments

Who received the money Research payments · program years 2019–2024

Bloodworks Northwest Bloodworks Organisation paid for research $23,844 3 payments
Waynee State University Organisation paid for research $16,693 3 payments
Childrens Hospital Los Angeles Teaching hospital · CA $9,970 1 payment
Tyler Buckner Hematology · Aurora, CO $8,742 3 payments
Shveta Gupta Pediatric Hematology-Oncology · Orlando, FL $3,751 2 payments
Robert Sidonio Pediatric Hematology-Oncology · Atlanta, GA $3,751 2 payments
Glaivy Batsuli Pediatric Hematology-Oncology · Palo Alto, CA $3,751 2 payments
Steven Pipe Pediatric Hematology-Oncology · Ann Arbor, MI $2,070 1 payment

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

3 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.